Safety and Performance Evaluation of Tulip Device in Healthy Overweight and Obese Volunteers

Not Applicable

• Conditions: Over Weight; Obesity
• Interventions: Device: Tulip capsule

• Registration Number: NCT01753609
• Lead Sponsor: Tulip Medical Ltd.

Brief Summary

The study will assess the safety and performance of an intragastric auto-inflating and degradable balloon

Detailed Description

The study will assess the safety and performance of an intragastric auto-inflating and degradable balloon, packed in a swallow-able capsule, in healthy subjects with 30 \< BMI≤ 35.

Study Timeline

• Status Verified: 2012-12
• Study First Submitted: 2012-12-17
• Study First Submitted QC: 2012-12-17
• Last Update Submitted: 2012-12-17
• Study First Posted: 2012-12-20
• Last Update Posted: 2012-12-20
• Study Start: 2013-01
• Primary Completion: 2013-03
• Study Completion: 2013-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• 21 ≤ Age <65 years
• 30 < BMI ≤ 35 kg/m2
• Healthy without any medication;
• No history of weight reduction of more than 5% of total body weight in the past 6 months;
• Normal blood count and chemistry;
• Hemoglobin level over 11;
• At least 3 bowel movements per week;
• Subject declares that he/she is able to go through gastroscopic examination;
• Subject is able and willing to give informed consent and follow protocol procedures.

Exclusion Criteria

• Any history or evidence of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results;
• History or evidence of any active liver disease. (abnormal liver functions: >1.5 times upper limit);
• History or symptoms of thyroid disease which is not controlled by medication;
• Abnormal gastrointestinal findings: Diaphragmatic hernia > 3 cm; Active peptic ulcer; Erosive gastritis; Gastric outlet obstruction;
• Subject with IBD
• Significant swallowing disorders;
• Past history of any gastrointestinal surgery (excluding uncomplicated appendectomy);
• Malabsorption disorders.
• Is taking medications that reduce gastric acidity
• Currently using pharmaceutical agents or food supplements for weight loss;
• History of or current eating disorder such as anorexia or bulimia or compulsory overeating.
• History of food Allergy;
• Subject with poor venous access;
• Is taking chronic aspirin or other non-steroidal anti-inflammatory agents, or other medications known to be gastric irritants;
• Have any coagulation problem and/or taking any anticoagulant medications;
• Evidence of current malignant disease;
• Have history of any acute disease (viral, bacterial, pain, accident) in the last 6 weeks.
• Female subject who are breastfeeding or have a positive pregnancy test at screening or at any time during the study;
• Inability to give written informed consent;
• History of alcohol or drug abuse within 6 months of screening;
• Mental disorders;
• Currently participating in an ongoing clinical study
• Any reasons making the patient a poor candidate in the opinion of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Tulip capsule	Tulip capsule	swallowing Tulip capsule for up to 29 days

Primary Outcome Measures

Name	Time	Method
Number of subjects with device related serious adverse events	36 days	Safety will be assessed descriptively by summarizing device related SAEs, gastroscopic examination, daily diary, vital sign measurements, physical examination and abdomen circumference.

Secondary Outcome Measures

Name	Time	Method
Patient assessment of capsule tolerability	36 days	Comfort and tolerability will be assessed by the patient and will be recorded in a daily diary. Tolerability evaluation will include: assessment of swallow ability, gastrointestinal comfort, defecation effort, appetite.
Satisfying evacuation of the balloon from the stomach after oral intake	36 days	Number of subjects showing satisfying evacuation of the balloon from the stomach after oral intake by means of a gastroscopic examination

Trial Locations

Locations (1)

Tel Aviv Sourasky Medical Center , Gastroenterology - Institute; 🇮🇱 Tel Aviv, Israel